MII IG Kerndatensatz-Modul Seltene Erkrankungen
2027.0.0-ballot - Germany

This page is part of the MII Implementation Guide Seltene Erkrankungen (v2027.0.0-ballot: 2027 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: MII VS Seltene Erkrankungen NBS Leitanalyten der Zielkrankheiten

Active Stand: 2026-09-14

Raw xml | Download


<ValueSet xmlns="http://hl7.org/fhir">
  <id value="mii-vs-seltene-nbs-target-analyte"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareablevalueset"/>
    <profile
             value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishablevalueset"/>
  </meta>
  <language value="de"/>
  <text>
    <status value="generated"/>
    <div xml:lang="de" lang="de"><hr/><p><b>German</b></p><hr/><p class="res-header-id"><b>Generated Narrative: ValueSet mii-vs-seltene-nbs-target-analyte</b></p><a name="de-mii-vs-seltene-nbs-target-analyte"> </a><a name="de-hcmii-vs-seltene-nbs-target-analyte"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profiles: <a href="http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareablevalueset.html">CRMI Shareable ValueSet</a>, <a href="http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishablevalueset.html">CRMI Publishable ValueSet</a></p></div><ul><li>Include these codes as defined in <a href="http://loinc.org"><code>http://loinc.org</code></a><span title="Version is not explicitly stated. No matching Code System found"> version Not Stated (use latest from terminology server)</span><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td><a href="https://loinc.org/29575-8/">29575-8</a></td><td>Thyrotropin [Units/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/38473-5/">38473-5</a></td><td>17-Hydroxyprogesterone [Mass/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/75217-0/">75217-0</a></td><td>Biotinidase [Enzymatic activity/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/54084-9/">54084-9</a></td><td>Galactose [Mass/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/29573-3/">29573-3</a></td><td>Phenylalanine [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/47679-6/">47679-6</a></td><td>Leucine [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/53175-6/">53175-6</a></td><td>Octanoylcarnitine (C8) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/50125-4/">50125-4</a></td><td>3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/53191-3/">53191-3</a></td><td>Tetradecenoylcarnitine (C14:1) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/38481-8/">38481-8</a></td><td>Carnitine free (C0) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/53199-6/">53199-6</a></td><td>Palmitoylcarnitine (C16) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/53235-8/">53235-8</a></td><td>Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in DBS</td></tr><tr><td><a href="https://loinc.org/45207-8/">45207-8</a></td><td>Glutarylcarnitine (C5-DC) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/42920-9/">42920-9</a></td><td>Isovalerylcarnitine (C5) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/53231-7/">53231-7</a></td><td>Succinylacetone [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/62320-7/">62320-7</a></td><td>T-cell receptor excision circle [#/volume] in DBS by NAA with probe detection</td></tr><tr><td><a href="https://loinc.org/54081-5/">54081-5</a></td><td>Hemoglobinopathies newborn screening panel</td></tr><tr><td><a href="https://loinc.org/92002-5/">92002-5</a></td><td>SMN1 gene [Cycle Threshold #] in DBS by NAA with probe detection</td></tr><tr><td><a href="https://loinc.org/53160-8/">53160-8</a></td><td>Propionylcarnitine (C3) [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/47700-0/">47700-0</a></td><td>Methionine [Moles/volume] in DBS</td></tr><tr><td><a href="https://loinc.org/48633-2/">48633-2</a></td><td>Trypsinogen I Free [Mass/volume] in DBS</td></tr></table></li></ul></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
    <valueCode value="shareable"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
    <valueCode value="publishable"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
    <valueCode value="computable"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes"/>
        <code value="package"/>
        <display value="Package"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/resource-approvalDate">
    <valueDate value="2026-09-02"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-topic">
    <valueCodeableConcept>
      <coding>
        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
        <code value="C4873"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <telecom>
        <system value="email"/>
        <value value="thomas.debertshaeuser@charite.de"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-editor">
    <valueContactDetail>
      <name value="Taskforce Core Data Set"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-reviewer">
    <valueContactDetail>
      <name value="Interoperability Working Group"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-reviewer">
    <valueContactDetail>
      <name value="National Steering Committee"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-endorser">
    <valueContactDetail>
      <name value="Interoperability Working Group"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-endorser">
    <valueContactDetail>
      <name value="National Steering Committee"/>
      <telecom>
        <system value="url"/>
        <value
               value="https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <url
       value="https://www.medizininformatik-initiative.de/fhir/ext/modul-seltene/ValueSet/mii-vs-seltene-nbs-target-analyte"/>
  <version value="2027.0.0-ballot"/>
  <name value="MII_VS_Seltene_NBS_TargetAnalyte"/>
  <title
         value="MII VS Seltene Erkrankungen NBS Leitanalyten der Zielkrankheiten"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2026-09-14T22:11:28+00:00"/>
  <publisher value="Medizininformatik Initiative"/>
  <contact>
    <name value="Medizininformatik Initiative"/>
    <telecom>
      <system value="url"/>
      <value value="https://www.medizininformatik-initiative.de/"/>
    </telecom>
  </contact>
  <description
               value="Leitanalyten der Zielkrankheiten des deutschen Neugeborenenscreenings nach G-BA Kinder-Richtlinie § 17 Abs. 1 (20 Zielkrankheiten) und 23 ff. (Mukoviszidose). Je Zielkrankheit der Analyt, über den sie im Screening erkannt wird."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="DE"/>
      <display value="Germany"/>
    </coding>
  </jurisdiction>
  <compose>
    <include>
      <system value="http://loinc.org"/>
      <concept>
        <code value="29575-8"/>
        <display value="Thyrotropin [Units/volume] in DBS"/>
      </concept>
      <concept>
        <code value="38473-5"/>
        <display value="17-Hydroxyprogesterone [Mass/volume] in DBS"/>
      </concept>
      <concept>
        <code value="75217-0"/>
        <display value="Biotinidase [Enzymatic activity/volume] in DBS"/>
      </concept>
      <concept>
        <code value="54084-9"/>
        <display value="Galactose [Mass/volume] in DBS"/>
      </concept>
      <concept>
        <code value="29573-3"/>
        <display value="Phenylalanine [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="47679-6"/>
        <display value="Leucine [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="53175-6"/>
        <display value="Octanoylcarnitine (C8) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="50125-4"/>
        <display
                 value="3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="53191-3"/>
        <display
                 value="Tetradecenoylcarnitine (C14:1) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="38481-8"/>
        <display value="Carnitine free (C0) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="53199-6"/>
        <display value="Palmitoylcarnitine (C16) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="53235-8"/>
        <display
                 value="Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in DBS"/>
      </concept>
      <concept>
        <code value="45207-8"/>
        <display value="Glutarylcarnitine (C5-DC) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="42920-9"/>
        <display value="Isovalerylcarnitine (C5) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="53231-7"/>
        <display value="Succinylacetone [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="62320-7"/>
        <display
                 value="T-cell receptor excision circle [#/volume] in DBS by NAA with probe detection"/>
      </concept>
      <concept>
        <code value="54081-5"/>
        <display value="Hemoglobinopathies newborn screening panel"/>
      </concept>
      <concept>
        <code value="92002-5"/>
        <display
                 value="SMN1 gene [Cycle Threshold #] in DBS by NAA with probe detection"/>
      </concept>
      <concept>
        <code value="53160-8"/>
        <display value="Propionylcarnitine (C3) [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="47700-0"/>
        <display value="Methionine [Moles/volume] in DBS"/>
      </concept>
      <concept>
        <code value="48633-2"/>
        <display value="Trypsinogen I Free [Mass/volume] in DBS"/>
      </concept>
    </include>
  </compose>
</ValueSet>